Chronic Obstructive Pulmonary Disease Drugs Market to Witness a Pronounce Growth by 2025

Document technical information

Format docx
Size 47.2 kB
First found Dec 18, 2017

Document content analysis

Category Also themed
not defined
no text concepts found





Chronic Obstructive Pulmonary Disease Drugs Market - Global
Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 2025
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease
which includes emphysema, chronic bronchitis, refractory asthma, and some
forms of bronchiectasis. This disease is characterized by increasing
breathlessness, wheezing, tightness in chest etc. In the early stages, there may
be no symptoms but the symptoms gradually increases in later stages.
Shortness of breath, chronic cough, fatigue, frequent flu, weight-loss etc. are
the symptoms exhibited in the later stages. Spirometry, chest X-ray, arterial
blood gas test etc. are the common tests for diagnosing COPD. Smoking,
genetic factors and environmental pollution are some major risk factor that
developed chronic obstructive pulmonary diseases.
Browse Full Research Report:
Based on drug type, the chronic obstructive pulmonary diseases market can
be segmented into anticholinergic, oral corticosteroid, beta2-agonists,
methylxanthines etc.). Among these, the oral corticosteroid segment is likely
to expand significantly compare to other drugs owing to extensive uses in the
treatment of all types of chronic obstructive pulmonary diseases. Based on
test type, the chronic obstructive pulmonary diseases drugs market can be
classified as lung functional test, chest x-ray test, CT scan, and others
(arterial blood gas test, genetic test etc.). Among these, the lung functional
test which is also called as spirometry test is expand at a high growth rate
because, the test is convenient, and accurately measure the lung function and
capacity. Based on application, the chronic obstructive pulmonary diseases
drugs market can be classified into emphysema, chronic bronchitis, and
refractory asthma. The chronic bronchitis segment is expand at a significant
rate due to increasing prevalence’s of the disease and it provides effective
and efficient treatment especially for the geriatric people. As per the Forum
of International Respiratory Societies (FIRS), chronic obstructive pulmonary
diseases affects more than 200 million individuals worldwide annually and
is likewise considered as one of the main sources of death comprehensively..
Attributable to these disturbing measurements, the utilization of pulmonary
drugs is probably going to pick up force, and thereby the market will also
grow accordingly. . Moreover, the advent of combination drugs is further
projected to propel the growth of the global chronic obstructive pulmonary
diseases drugs market. However, unknown etiology of chronic obstructive
pulmonary diseases in medical industry and lack of proper awareness about
the effect of chronic obstructive pulmonary diseases would might hinder the
growth of the market.
In terms of region, the global chronic obstructive pulmonary diseases drugs
market can be segmented into North America, Europe, Asia Pacific, Latin
America and Middle East & Africa. North America dominates global market
followed by Europe due to growing use of the drugs for treatment of COPD
and high awareness regarding treatment. Increasing environmental pollution,
rapidly growing the number smoker’s and the growing prevalence’s of
pulmonary disease are like to attribute the market of chronic obstructive
pulmonary diseases drugs in Asia Pacific region. Advancements in drug
delivery, increasing per capita income, rising expenditure on personal care
and growing incidences of diseases especially chronic pulmonary diseases are
likely to augment the market for chronic obstructive pulmonary diseases in
Middle East & Africa region during the forecast period.
Major players operating in the global chronic obstructive pulmonary diseases
market include ., Boehringer Ingelheim GmbH, Teva Pharmaceutical
Industries Ltd., AstraZeneca plc, Novartis AG, Bayer AG, GlaxoSmithKline
plc, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Actelion
Pharmaceuticals, IncSunovion Pharmaceuticals, Inc. and others.
Browse Full Press Release:
Press Release
About Us
Transparency Market Research (TMR) is a global market intelligence
company providing business information reports and services. The
company’s exclusive blend of quantitative forecasting and trend analysis
provides forward-looking insight for thousands of decision makers. TMR’s
experienced team of analysts, researchers, and consultants use proprietary
data sources and various tools and techniques to gather and analyze
TMR’s data repository is continuously updated and revised by a team of
research experts so that it always reflects the latest trends and information.
With extensive research and analysis capabilities, Transparency Market
Research employs rigorous primary and secondary research techniques to
develop distinctive data sets and research material for business reports.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: [email protected]

Report this document